CRDF News and Press, Cardiff Oncology Inc. From 06/09/22

You can’t argue that biotech stocks were hit hard during the 2022 stock market crash. But that doesn’t mean opportunity was utterly stifled. Depending on your outlook and investment style, volatility has become a considerable asset to some. You know what I’m talking abo...

Gainers: Power bridge Technologies (PBTS) +177%. Applied UV (AUVI) +50%. Cardiff Oncology (CRDF) +38%. DBV Technologies (DBVT) +28%. View (VIEW) +24%. Viracta Therapeutics (VIRX) +22%. Finger Motion (FNGR) +21%. Scien joy (SJ) +20%. Aero Clean Technologies (AERC) +19%. Akso Health Group (AHG)...

Cardiff Oncology started taking a beating from the early days of the biotech bear market, in September 2021. The company is the first to correctly target PLK1, a target in several solid tumors, in all KRAS-mutated cancers. The stock has consistently fallen on what I view as excell...

The following slide deck was published by Cardiff Oncology, Inc. in conjunction with this event. For further details see: Cardiff Oncology (CRDF) Investor presentations - Slideshow

Despite producing decent data, the stock has kept falling. Today it is in the penny stock zone, and we do not recommend penny stocks as investments. However, Pfizer's small stake is a silver lining. For further details see: Cardiff Oncology: Risky Investment

Cardiff Oncology to Present at the H.C. Wainwright Global Investment Conference PR Newswire SAN DIEGO , May 17, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapie...

Cardiff Oncology press release (NASDAQ:CRDF): Q1 GAAP EPS of -$0.25 misses by $0.02. Royalty Revenue of $0.07M (flat Y/Y). Cash, cash equivalents, and short-term investments of approximately $129.4 million as of March 31, 2022 For further details see: Cardiff Oncology GAAP EPS of -$0.25...

Cardiff Oncology Reports First Quarter 2022 Results and Provides Business Updates PR Newswire Reported new Phase 1b /2 data from lead KRAS-mutated metastatic colorectal cancer (mCRC) clinical program showing objective response rate and median progression-free survi...

Amid a down market, Guardant shares are trading at a bargain to their estimated value. Meanwhile, Guardant continues to procure robust sales increases and narrowed its bottom line depreciation. The recent Epic deal for its diagnostics to reach over 250M patients is a transformativ...

Cardiff Oncology (NASDAQ:CRDF) shares are trading lower in the post-market Tuesday after the cancer-focused biotech announced that its chief medical officer (CMO) Katherine L. Ruffner would leave the company effective Apr. 22 to pursue a new opportunity. However, Dr. Ruffner has agreed to sup...